img

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Insights, Forecast to 2034

AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
Market Analysis and InsightsGlobal Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market is expected to reach to US$ 807 million in 2024, with a positive growth of %, compared with US$ 767 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy industry is evaluated to reach US$ 1106.4 million in 2029. The CAGR will be 5.4% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
Segment by Type
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)

Segment by Application


Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy introduction, etc. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Single-stranded AAV (ssAAV)
1.2.3 Self-complementary AAV (scAAV)
1.3 Market by Application
1.3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hemophilia
1.3.3 Ophthalmology
1.3.4 Lysosomal Storage Disorders
1.3.5 Neurological Disorders
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Perspective (2018-2029)
2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Trends by Region
2.2.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Region (2018-2024)
2.2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Region (2024-2029)
2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Dynamics
2.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Trends
2.3.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
2.3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
2.3.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Players
3.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2018-2024)
3.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Players (2018-2024)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio
3.4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022
3.5 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Head office and Area Served
3.6 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Product and Application
3.7 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Breakdown Data by Type
4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Type (2018-2024)
4.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029)
5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Breakdown Data by Application
5.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Application (2018-2024)
5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
6.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
6.2.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2024)
6.2.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
6.2.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
6.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
6.3.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2024)
6.3.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
6.3.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
6.4 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
6.4.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2024)
6.4.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
7.2.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2024)
7.2.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
7.2.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
7.3.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2024)
7.3.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
7.3.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
7.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
7.4.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2024)
7.4.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
8.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
8.2.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2024)
8.2.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
8.2.3 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
8.3 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
8.3.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2024)
8.3.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
8.3.3 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
9.2 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
9.2.1 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2024)
9.2.2 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
9.2.3 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
9.3 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
9.3.1 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2024)
9.3.2 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
9.3.3 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
9.4 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
9.4.1 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2024)
9.4.3 Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
10.2.1 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
10.3.1 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
10.4.1 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 BioMarin Pharmaceutical
11.1.1 BioMarin Pharmaceutical Company Details
11.1.2 BioMarin Pharmaceutical Business Overview
11.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.1.4 BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
11.1.5 BioMarin Pharmaceutical Recent Developments
11.2 Sangamo Therapeutics
11.2.1 Sangamo Therapeutics Company Details
11.2.2 Sangamo Therapeutics Business Overview
11.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.2.4 Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
11.2.5 Sangamo Therapeutics Recent Developments
11.3 Amicus Therapeutics
11.3.1 Amicus Therapeutics Company Details
11.3.2 Amicus Therapeutics Business Overview
11.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.3.4 Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
11.3.5 Amicus Therapeutics Recent Developments
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.4.4 Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
11.4.5 Roche Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.5.4 Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
11.5.5 Pfizer Recent Developments
11.6 NightstaRx
11.6.1 NightstaRx Company Details
11.6.2 NightstaRx Business Overview
11.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.6.4 NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
11.6.5 NightstaRx Recent Developments
11.7 MeiraGTx
11.7.1 MeiraGTx Company Details
11.7.2 MeiraGTx Business Overview
11.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.7.4 MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
11.7.5 MeiraGTx Recent Developments
11.8 Sarepta Therapeutics
11.8.1 Sarepta Therapeutics Company Details
11.8.2 Sarepta Therapeutics Business Overview
11.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.8.4 Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
11.8.5 Sarepta Therapeutics Recent Developments
11.9 Neurocrine Biosciences
11.9.1 Neurocrine Biosciences Company Details
11.9.2 Neurocrine Biosciences Business Overview
11.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.9.4 Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
11.9.5 Neurocrine Biosciences Recent Developments
11.10 Voyager Therapeutics
11.10.1 Voyager Therapeutics Company Details
11.10.2 Voyager Therapeutics Business Overview
11.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.10.4 Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
11.10.5 Voyager Therapeutics Recent Developments
11.11 Asklepios Biopharmaceutical
11.11.1 Asklepios Biopharmaceutical Company Details
11.11.2 Asklepios Biopharmaceutical Business Overview
11.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.11.4 Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
11.11.5 Asklepios Biopharmaceutical Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Single-stranded AAV (ssAAV)
Table 3. Key Players of Self-complementary AAV (scAAV)
Table 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2024) & (US$ Million)
Table 7. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2018-2024)
Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2024-2029)
Table 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Trends
Table 11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
Table 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
Table 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
Table 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2018-2024) & (US$ Million)
Table 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Players (2018-2024)
Table 16. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)
Table 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Ranking 2021 VS 2022 VS 2024
Table 18. Global 5 Largest Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (CR5 and HHI) & (2018-2024)
Table 19. Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Headquarters and Area Served
Table 20. Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Product and Application
Table 21. Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 24. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2018-2024)
Table 25. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2024-2029)
Table 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Application (2018-2024)
Table 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Application (2024-2029)
Table 31. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 32. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 33. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 34. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 35. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2024) & (US$ Million)
Table 37. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 39. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 40. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 41. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 42. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2024) & (US$ Million)
Table 44. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 45. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 46. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 47. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 48. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 49. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 50. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 51. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 52. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 54. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2024) & (US$ Million)
Table 55. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2024-2029) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2024) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 61. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 63. BioMarin Pharmaceutical Company Details
Table 64. BioMarin Pharmaceutical Business Overview
Table 65. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 66. BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024) & (US$ Million)
Table 67. BioMarin Pharmaceutical Recent Developments
Table 68. Sangamo Therapeutics Company Details
Table 69. Sangamo Therapeutics Business Overview
Table 70. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 71. Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024) & (US$ Million)
Table 72. Sangamo Therapeutics Recent Developments
Table 73. Amicus Therapeutics Company Details
Table 74. Amicus Therapeutics Business Overview
Table 75. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 76. Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024) & (US$ Million)
Table 77. Amicus Therapeutics Recent Developments
Table 78. Roche Company Details
Table 79. Roche Business Overview
Table 80. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 81. Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024) & (US$ Million)
Table 82. Roche Recent Developments
Table 83. Pfizer Company Details
Table 84. Pfizer Business Overview
Table 85. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 86. Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024) & (US$ Million)
Table 87. Pfizer Recent Developments
Table 88. NightstaRx Company Details
Table 89. NightstaRx Business Overview
Table 90. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 91. NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024) & (US$ Million)
Table 92. NightstaRx Recent Developments
Table 93. MeiraGTx Company Details
Table 94. MeiraGTx Business Overview
Table 95. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 96. MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024) & (US$ Million)
Table 97. MeiraGTx Recent Developments
Table 98. Sarepta Therapeutics Company Details
Table 99. Sarepta Therapeutics Business Overview
Table 100. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 101. Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024) & (US$ Million)
Table 102. Sarepta Therapeutics Recent Developments
Table 103. Neurocrine Biosciences Company Details
Table 104. Neurocrine Biosciences Business Overview
Table 105. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 106. Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024) & (US$ Million)
Table 107. Neurocrine Biosciences Recent Developments
Table 108. Voyager Therapeutics Company Details
Table 109. Voyager Therapeutics Business Overview
Table 110. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 111. Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024) & (US$ Million)
Table 112. Voyager Therapeutics Recent Developments
Table 113. Asklepios Biopharmaceutical Company Details
Table 114. Asklepios Biopharmaceutical Business Overview
Table 115. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
Table 116. Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024) & (US$ Million)
Table 117. Asklepios Biopharmaceutical Recent Developments
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type: 2022 VS 2029
Figure 3. Single-stranded AAV (ssAAV) Features
Figure 4. Self-complementary AAV (scAAV) Features
Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application: 2022 VS 2029
Figure 7. Hemophilia Case Studies
Figure 8. Ophthalmology Case Studies
Figure 9. Lysosomal Storage Disorders Case Studies
Figure 10. Neurological Disorders Case Studies
Figure 11. Others Case Studies
Figure 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report Years Considered
Figure 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region: 2022 VS 2029
Figure 16. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Players in 2022
Figure 17. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2022
Figure 19. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 21. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 22. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 23. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY (2018-2029) & (US$ Million)
Figure 26. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 27. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 28. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 29. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY (2018-2029) & (US$ Million)
Figure 36. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 37. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 38. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY (2018-2029) & (US$ Million)
Figure 39. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 40. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 41. Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2018-2029)
Figure 42. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. China Taiwan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2018-2029)
Figure 50. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2018-2029)
Figure 51. Middle East, Africa, and Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2018-2029)
Figure 52. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. GCC Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. BioMarin Pharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
Figure 59. Sangamo Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
Figure 60. Amicus Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
Figure 61. Roche Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
Figure 62. Pfizer Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
Figure 63. NightstaRx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
Figure 64. MeiraGTx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
Figure 65. Sarepta Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
Figure 66. Neurocrine Biosciences Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
Figure 67. Voyager Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
Figure 68. Asklepios Biopharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2018-2024)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries